Seeking Alpha

InterMune (ITMN) fails to win FDA approval for a lung treatment that analysts estimated would...

InterMune (ITMN) fails to win FDA approval for a lung treatment that analysts estimated would bring in more than $1B in annual sales. Outside advisers to the FDA had recommended approval of the drug in March. Shares -80.7% AH. (PR)
From other sites
Comments (3)
  • danielmik1
    , contributor
    Comments (8) | Send Message
     
    Hope you bounce back ITMN..

     

    You guys hang in there..
    4 May 2010, 07:14 PM Reply Like
  • ragedmaximus
    , contributor
    Comments (47) | Send Message
     
    wuz up in ah i see it did go back on half the money sited?
    4 May 2010, 09:02 PM Reply Like
  • danielmik1
    , contributor
    Comments (8) | Send Message
     
    hard to say it depends on the confidence level.
    Worse cause scenerio was a 20 percent loss but 80% is tragic!!
    I have been seeing alot of activity, hopefully prices will regain to some degree of sanity..
    5 May 2010, 10:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs